A5071436343- Multiple Sclerosis Research Studies
- Systemic Lupus Erythematosus Research
- Peripheral Neuropathies and Disorders
- Polyomavirus and related diseases
- Glioma Diagnosis and Treatment
- Systemic Sclerosis and Related Diseases
- Epilepsy research and treatment
- Ultrasound and Hyperthermia Applications
- Brain Metastases and Treatment
- Blood Coagulation and Thrombosis Mechanisms
- Herpesvirus Infections and Treatments
- Cancer Treatment and Pharmacology
- Platelet Disorders and Treatments
- Blood properties and coagulation
- Rheumatoid Arthritis Research and Therapies
- Monoclonal and Polyclonal Antibodies Research
- Pharmacological Effects and Toxicity Studies
- Immunotherapy and Immune Responses
- Autoimmune Neurological Disorders and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Cerebral Venous Sinus Thrombosis
- Hereditary Neurological Disorders
- RNA Interference and Gene Delivery
- Histone Deacetylase Inhibitors Research
- Diabetic Foot Ulcer Assessment and Management
Istituti Fisioterapici Ospitalieri
2014-2023
Istituti di Ricovero e Cura a Carattere Scientifico
2019-2023
I.R.C.C.S. Oasi Maria SS
2019
University of Rome Tor Vergata
2016
Cancer Institute (WIA)
2014
National Cancer Institute
2010-2014
Institute of Neurological Sciences
2009
Nuovo Ospedale San Giovanni di Dio
2004
Sapienza University of Rome
1995-1999
University of Leicester
1998
fatigue is a common and disabling symptom in multiple sclerosis (MS). In this study we evaluated if associated with different demographic clinical features of MS.A survey was performed on 507 consecutive patients affected by clinically definite MS referred to our centre between January 1 December 31, 1993. During the examination were asked answer brief questionnaire. To evaluate probability occurrence association several covariant factors (age, sex, duration, disease form, severity, month...
Multiple sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system. Several evidences suggest that MS can be considered a multi-factorial in which both genetics and environmental factors are involved. Among proposed candidates, growing results support involvement oxidative stress (OS) pathology. The aim this study was to investigate role OS event exacerbations on serum relapsing-remitting (RR-MS) patients, either relapsing or remitting phase, with...
OBJECTIVE: To evaluate whether recombinant human interferon-beta-1a significantly affects disease activity as measured by a reduction in the number and volume of Gd enhancing lesions on monthly MRI. The study also evaluated effect six-monthly T2 weighted abnormality relapse frequency. METHODS: After baseline scan six month pretreatment period, 68 patients were randomly assigned to receive either 3 MIU or 9 subcutaneous injection three times week for months. All examined enhanced MRI every...
Background: Epilepsy is one of the most common symptoms brain tumors. It often drug resistant and generally worsen patients' quality life (QoL). Brain tumors release glutamate among other mediators, contributing to seizures onset, this accompanied by an increased AMPA receptors' expression on neuronal cells' membrane. Perampanel (PER) a relatively new antiseizure medication (ASM) that acts as selective non-competitive antagonist. Given its mechanism action, we aimed evaluate through...
Carbapenem-resistant Klebsiella pneumoniae (CRKP) is a prominent cause of nosocomial infections associated with high rates morbidity and mortality, particularly in oncological patients. The hypermucoviscous (HMV) phenotype biofilm production are key factors for CRKP colonization persistence the host. This study aims at exploring impact virulence on mortality A total 86 were collected between January 2015 December 2019. Carbapenem resistance-associated genes, antibiotic susceptibility, HMV...
The aim of the study was to evaluate predictive power baseline gadolinium (Gd) enhanced MRI in relation subsequent clinical and activity. Sixty eight patients with clinically definite relapsing-remitting multiple sclerosis had a Gd were followed up by monthly for six months. occurrence relapses during follow period predicted presence at least one enhancing lesion on (P < 0.05). number volume lesions significantly associated both observed 0.0001) accumulation abnormality T2 weighted images...
Abstract Objective Possible loss of efficacy and potential interactions between antiepileptic drugs (AEDs) chemotherapy could complicate the management patients with brain tumor‐related epilepsy (BTRE) that may expose to an increased risk adverse events. Perampanel (PER) is a highly selective, noncompetitive, alpha‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazole propionic acid (AMPA)‐type glutamate receptor antagonist. This study evaluates effectiveness, QoL, cognition, mood PER in add‐on therapy BTRE...
Introduction: Epilepsy occurs in 35–70% of patients with gliomas; glutamate plays a central role via AMPA-receptor activation, which is involved both seizure activity and tumor growth. We conducted retrospective study on brain tumor-related epilepsy (BTRE) treated perampanel add-on (PER) for 12 months, to evaluate efficacy tollerability, according real-life clinical practice.Materials methods: Medical records eleven (9 males, mean age 54 years) glioma PER add-on, inadequate control or...
Objectives - The present investigation was aimed at establishing whether interferon (IFN)-β would induce the synthesis of autoantibodies in patients affected by multiple sclerosis (MS). Materials and methods titres different were measured a group 68 relapsing-remitting MS before during treatment with human recombinant IFN-βla (3 MIU or 9 subcutaneously 3a week). ANA, anti-thyroid, anticardiolipin serum assayed all cases: when found positive to ANA>1: 40, they also tested for anti-DNA...
Natalizumab, an anti-alpha4 integrin monoclonal antibody inhibiting the adhesion of lymphocytes to endothelium, is a widely accepted drug treatment for relapsing-remitting multiple sclerosis (RRMS). A peripheral increase T and B has already been observed as early effect. This retrospective observational study was aimed evaluate lymphocyte subsets during long-term follow-up. We included 23 RRMS patients treated with natalizumab at least 24-48 months who had pretreatment evaluation. Baseline...
The aim of this study was to investigate whether a concomitant treatment with recombinant interferon beta la (rIFNβ-la) modifies the effect steroids on blood-brain barrier (BBB) in relapsing remitting MS patients, as evaluated by enhanced MRI brain. We 19 patients clinical relapse treated only intravenous methylprednisolone (IVMP; 1 g daily for 6 days), and 10 who experienced were IVMP (1 days) during an rIFNβ-la period. number volume enhancing lesions analyzed four serial MR images obtained...
To further evaluate the relationship between clinical disability and Magnetic Resonance Imaging (MRI) lesion burden, we examined 85 patients with clinically definite multiple sclerosis (54 relapsing-remitting 31 secondary progressive). This cross-sectional study reports on correlations total infratentorial volume both T1 T2 weighted images, overall physical measured by Expanded Disability Status Scale, ambulation index individual functional systems. Assessment of hypointense load images...
<b><i>Background/Aims:</i></b> The relationship between multiple sclerosis (MS) and anemia has not been clarified sufficiently. In this retrospective, cross-sectional, case-control study we evaluated in MS patients: (1) prevalence of relative to sex- age-matched controls; (2) relationships patients' demographic, clinical drug-related characteristics anemia; (3) effect on the risk developing MS. <b><i>Methods:</i></b> 187 consecutive patients...